Atypical Serum Creatine Kinase Isoenzyme Pattern Caused by Complexing of Creatine Kinase-BB with Immunoglobulins G and A by Jockers-Wretou, Evangelia & Plessing, Elisabeth
Jockers-Wretou and Plessing: Creatine kinase-BB complex with immunoglobulins G and A 731
J. Clin. Chem. Clin. Biochem.
Vol. 17,1979, pp. 731-737
Atypical Serum Creatine Kinase Isoenzyme Pattern Caused by Complexing of Creatine Kinase-BB
with Immunoglobulins G and A 1 ) , 2 )
By Evangelia Jockers-Wretou and Elisabeth Plessing
Institut für Organische Chemie, Biochemie und Isotopenforschung der Universität Stuttgart
(Received June 21/August l, 1979)
In commemoration of Professor Dr. Gabor Szasz
Summary: 12 cases are described, which show high serum creatine kinase-BB levels, as well as atypical creatine kinase
activity band located between normally migrating creatine kinase-MM and creatine kinase-MB. It is shown that the
altered properties of the serum creatine kinase-BB, namely its molecular size, heat resistance, electrophoretic mobility,
but not its immunological behavior, are caused by complexing with kappa-chains of immunoglobulins G or A. The
complex occurring in vivo could also be produced in vitro by using purified patients' IgG and human creatine kinase-
BB.
The interaction of creatine kinase-BB with immunoglobulins possibly protects the enzyme against intravascular
degradation in vivo, and may therefore account for the high creatine kinase-BB levels observed in these patients.
Atypisches Isoenzymmuster von Kreatinkinase im Serum infolge Komplexbildung von Kreatinkinase-BB mit Immun·
globulin G und A
Zusammenfassung: Es werden 12 Falle beschrieben, die eine erhöhte Kreatinkinase-BB-Aktivität im Serum als auch
eine atypische Kreatinkinase-Bande zwischen Kreatinkinase-MM und Kreatinkinase-MB aufweisen. Es wird gezeigt,
daß die veränderten Eigenschaften der Serum-Kreatinkinase-BB, nämlich Molekulargewicht, Hitzestabilität, elektro-
phoretische Mobilität, aber nicht das immunologische Verhalten, auf die Bindung des Enzyms an kappa-Ketten der
Immunpglobuline G und A zurückzuführen sind. Der in vivo auftretende Komplex konnte auch in vitro reproduziert
werden und zwar mit gereinigtem Patienten-IgG und humaner Kreatinkinase-BB.
Die Bindung zwischen Kreatinkinase-BB und Immunoglobulinen schützt möglicherweise das Enzym in vivo gegen
intraväsale Degradation und könnte somit die bei diesen Patienten auftretende erhöhte Kreatinkinase-BB-Aktivität
hervorrufen.
Introduction 2. unusually high concentrations of creatine kinase-BB
and
Occurrence of the creatine kinase (EC 2.7.3.2) isoensyme
 3 appearance of creatine kinase-BB in the
BB (creatine kinase-BB) in patient sera without correlation ^^^
to any specific disease has recently been reported (1 ,2).
It was designated as "idiopathic creatine kinase-BB" (1), The present report was initiated by the hypothesis that
or as a 'Variant creatine kinase ispenzyme" (2). The the above mentioned properties of creatine kinase-BB
reported cases had three properties in common, namely could be due to interaction of the enzyme with a serum
factor, the results of 1 2 cases showing atypical iso-
1 . an atypical ereatine kinase activity band located enzyme pattern as well as high creatine kinase-BB levels
between normally migrating creatine kinase-MM and in the serum are described.
creatine kinase-MB,
Material and Methods
*i QnnnnrteH hv the Deutsche Forschungsgemeinschaft ' Patients ' sera: The reported cases were detected in several
* ISES* fZSS^^^^^V^ of Clinical hospitals by their abnormally high creatine kinase-MB activities
Che^iiltry B?fehton 1979 with the immunoinhibition test (Merck). Serum samples
0340-076X/79/00 1 7-073 1 $2.00
© by Walter de Gruyter & Co. · Berlin · New York
732 Jockers-Wretou and Plessing: Creatine kinase-BB complex with immunoglobulins G and A
were generously left at the authors' disposal for further
characterization. The samples were stored without any thiol
at -25°C until use. During the experiments they were kept
at 4 °C after addition of 2-mercaptoethanol (final concen-
tration 20 mmol/1).
Enzyme assay: Creatine kinase activity measurements were
made at 25 °C by the RosalkiOliver method (3) using the
kit "CK-NAC-activated" (Boehringer, Mannheim), the reaction
was monitored with an Eppendorf photometer at 365 nm.
Creatine kinase isoenzyme measurements were done by the
immunotitration assay developed in this laboratory and modified
as reported previously (4,5), using purified IgG from sheep anti-
sera against human creatine kinase-MM and creatine kinase-BB
(Merck, Darmstadt). Creatine kinase-BB activity in column
eluates was assayed by the immunoinhibition test "CK-MB,
NAC activated" (Merck). The results were not multiplied by
two (6).
Electrophoresis was performed at 4 °C on cellulose acetate strips
(Macherey & Nagel, Düren) in 30 mmol/1 Veronal buffer, pH 8.6
at 200 V for one hour. Creatine kinase activity bands were
visualized by overlaying the membranes with an agarose-substrate
mixture and incubating for 30-60 min at 37 °C. The strips were
dried, viewed in UV-light and finally stained with Coomassie
Brillant Blue G 250 (Serva, Heidelberg) (2.5 g/1 in methanol:
water: acetic acid, volumes 5 + 5 + 1). Isoelectric focussing
studies were performed on Ampholine PAG-plates (LKB, Karls-
ruhe), pH 3.5-9.5, with a Desaga apparatus, for 1.5 hour. After
washing in distilled water for 15 min the polyacrylamide gel-
plates were stained for creatine kinase activity as described
above.
Creatine kinase isoenzymes: Crystalline creatine kinase-MM
from human muscle was purified as reported previously (4).
Human brain obtained at autopsy was used as source of
creatine kinase-BB. Extracts were made in Tris/HCl buffer
pH 8.0 (50 mmol/1, 1 mmol/1 EDTA, 10 mmol/1 KC1, 20 mmol/1
2-mercaptoethanol). The enzyme was partly purified by (NH^-
SO4-fractionation and chromatography on Sephadex-£-200
(Pharmacia, Sweden). Hybridization of creatine kinase-MM
and creatine kinase-BB was performed in 6 mol/1 urea. After
dialysis against Tris-buffer pH 8.0 (50 mmol/1,1 mmol/1 EDTA,
20 mmol/12-mercaptoethanol) the relative isoenzyme concen-
trations were estimated immunologically. The isoenzyme mix-
ture was diluted in normal heat-inactivated serum (serum
matrix) and used as a control for the electrophoretic runs.
Purification of immunoglobulins: Immunoglobulins G, M and A
were estimated by single radial immunodiffusion on agar plates
(Tri-Partigen, Behringwerke, Marburg). Immunoglobulins G
were purified from the patients' sera on a Protein A-Sepharose
CL-4B column (Pharmacia), using an acid eluent (0.1 mol/1
glycine/HCl, pH 3.0) (7). the eiuate was immediately neu-
tralized and concentrated through selectron ultramembranes
(Schleicher & Schüll, Dassel). The concentration of the purified
IgG was estimated by its absorbance at 280 nm, taking
A i^ = 14.6 (8).
280
Immunological techniques: Double diffusion, immunoelectro-
phoresis and two dimensional "rocket" immunoelectrophoresis
were carried out on agarose gels (8 g/l) according to the corre-
sponding techniques by Ouchterlony (9), Grabar (10) and Laurett
(11). The agarose plates were washed twice in 9 g/l NaCl and
stained for creatine kinase activity as described for the electro-
pherograms. Control sera and antisera against human plasma
proteins were purchased from Behringwerke.
Results
Age, sex, diagnosis and creatine kinase isoenzyme serum
activities of the reported cases are summarized in table 1.
Creatine kinase serum activity varied from 32 to 349
U/l and the relative creatine kinase-BB was 10-95 %
(16—300 U/l). Serum protein electrophoresis was
without any particularities. Concentrations of immuno-
globulins G, A and M were within normal ranges.
Stability
The serum creatine kinase activity was stable for several
days at 25 °C and for at least two months at 4 °C. A
remarkable stability was further observed at 37 °C as
shown in figure la for case no. 11. In contrast, incubation
of human creatine kinäse-BB in serum matrix resulted in
approximately 80 % loss of the activity within one hour
(fig. 10).
Tab. 1. Diagnosis, age, sex and serum creatine kinase (CK) isoenzyme activities of the patients.
Case
no.
1
2
3
4*#*
5
6
7
8
9
10
11 .
12 a)
b)
c)
Age
81
60
60
68
65
28
78
64
50
55
47
71
Sex
9
6
9
6
0
9
9
9
9
d
9
6
CK activity
(U/l)
74
32
87
349
120
112
116
111
73
47
130
266
148
78
CK-MM
(%)
22
50
36
14
16
22
5
38
70
.52
22
74
85
57
CK-MB
(%)
11
0
16
. 0
0
0
0
29
5
0
0
16
0
0
CK-BB
(%)
67
50
48
86
84
78
95
32
25
48
78
10
15
22
Diagnosis
cerebral vase, insufficiency
cerebral insult*
unknown
rehabilitation after m. infarct
angina pectoris
asthma bronchiale
angina pectoris
m. infarct
m. infarct**
ischemic chest pain
degenerative coronary disease
m. infarct 1st****
2nd
3rd
* 2 weeks after injury
** 4 days after onset
*** Cases no. 4,5,6,7 and 8 correspond to no. 1,2,4,5 and 6 reported in I.e. (19)
**** days after onset
J. Clin. Chem. Clin. Biochem. / VoL 17,1979 / No. 11
Jockers-Wretou and Plessing: Creatine kinase-BB complex with immunoglobulins G and A 733
801
Fig. 1. Thermal stability of aeatine kinase activity at 37 °C.
α) serum no. 11,0) human creatine kinase-BB in serum
matrix (100 U/l). (Aliquots were sampled for enzyme
assay at the times shown). All points are means of three
estimations with the representative SD shown.
Immunotitration assay
The immunotitration curves of serum no. 11 and of
native creatine kinase-BB in a serum matrix against anti-
human creatine kinase-BB immunoglobulins are compa-
red in figure 2. Slope and titration point of both curves
are very similar (with respect to the relative creatine
kinase-BB in the serum). A slight difference was obser-
ved as increasing amounts of antibody resulted in an
increase of the residual activity in the patient serum
curve.
Electrophoresis: Electrophoretic patterns of some serum
samples are shown in figure 3. A single creatine kinase
activity band in the 0-globulin region was located between
normally migrating creatine kinase-MM and creatine
kinase-MB, except for case no. 5. The creatine kinase
activity band migrated in this serum very close to the
creatine kinase-MB band of the control. The cathodal
band corresponding to creatine kinase-MM was observed
in some sera (9 arid 10). In many cases, however, the
MM-band was not always detectable as indicated by the
20
0 50 100
Anti-Creatine kinase ΘΒ IgG [μ\]
Fig. 2. Immunotitration assay of a) serum no. 11 aeatine kinase
activity and β) human creatine kinase-BB in serum matrix.
Aliquots of the patient's serum (50 mil) and of human
creatine kinase-BB in serum matrix (40 mU), both contain-
ing 3.5 % polyethyleneglycol, were incubated with sheep
IgG against human creatine kinase-BB. Tris buffer, pH 8.0
(0.05 mol/1; 1 mmol/1 EDTA, 20 mmol/1 2-mercaptoetha-
nol) was added to a final volume of 450 μΐ. The residual
activity is expressed as a percentage of the control after
incubation (l h 25 °C) and centrifugation.
dashed lines, or it was even totally undetectable. Case
no. 12 (not shown) revealed the atypical band and a
normally migrating creatine kinase-MB band as well.
Isoelectric focussing studies showed an analogous
behavior. Creatine kinase activity bands were located
at the position of creatine kinase-MM and between
creatine kinase-MM and creatine kinase-MB (pH 5.6-
6.8). Furthermore, a strong naturally occurring
fluorescent band was seen at pH 4.5, the isoelectric
point of normally migrating creatine kinase-BB.
Increasing amounts of native creatine kinase-BB were
added to a constant volume of the patients' sera. Sub-
sequently, the samples were analyzed electrophoretic-
ally and assayed for creatine kinase activity. A shown
in figure 4, the exogenous creatine kinase-BB migrated
first to the same position as the atypical band. Further
addition of creatine kinase-BB revealed the anodically
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Fig. 3. Electropherograms of creatine kinase isoenzymes in some serum samples.
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Fig. 4. Electropherogram of serum no. 7 after addition of increasing amounts of human creatine kinase-BB.
Exogenous creatine kinase-BB was added to 100 μΐ serum at the following concentrations. Left to right: control, no. 7, no. 7
with 6 mU creatine kinase-BB, no. 7 with 30 mU creatine kinase-BB, no. 7 with 120 mil creatine kinase-BB.
migrating creatine kinase-BB in addition to the atypical
band. The measured creatine kinase activity of the
samples was compared with their theoretical activity
as calculated by addition of the endogenous and exo-
genous enzyme activities. This measured activity was
30 % less than the calculated activity in all cases. These
results indicated the presence of a serum factor capable
of forming a stable creatine kinase-BB complex with a
limited creatine kinase-BB activity.
Efforts to precipitate the creatine kinase-BB factor
complex with anti-human creatine kinase-BB serum
failed. In contrast, exogenous added creatine kinase-BB
migrated normally after the patients' sera were treated
with antiserum against human plasma proteins. This
indicated the factor(s) to be a normal component of
human serum.
Column chromatography:
Two peaks showing creatine kinase activity were ob-
tained after serum no. 11 chromatography on Sephadex
G-200 (fig. 5). A small peak (II) corresponding to a
molecular mass of 80 000 was identified as creatine
kinase-MM. A second peak (I) of higher molecular mass
(240 000) exhibited only creatine kinase-BB activity.
Immunological studies
The Laurell technique was used to analyze the eluate
from the Sephadex column containing creatine kinase-
BB activity, using a polyvalent antiserum against
human serum proteins. When stained for creatine
kinase activity one of the precipitin peaks showed
strong fluorescence. The corresponding serum protein
was identified as IgG by specific anti-IgG serum. All
patients' sera assayed by this technique demonstrated
a fluorescent precipitin peak of IgG, except case no. 5.
In this case the complexing protein was identified as
IgA, as shown in figure 6.
30 40 50
Fraction number
Fig. 5. Elation pattern of serum no. 11 creatine kinase activity
from a Sephadex G-200 column. 3 ml serum no. 11 were
applied to the column and eluted with Tris buffer pH 8.0
(0.05 mol/1,1 mmol/1 EDTA, 20 mmol/1 2^mercapto-
ethanol). Fractions were assayed for total creatine kinase
activity (Δ Δ) and for creatine kinase-BB activity
(o o) using the immunoinhibition assay. Column
dimensions: 25 X 850 mm, void volume: 93 ml, fraction
volume: 1.6 ml.
It is noteworthy that only one side of the peak shows
creatine kinase activity. Figure 7 demonstrates the
patterns observed in the technique of Grabar for two
other cases. Precipitiri arcs produced by immuno^
electrophoresis of the patients' sera versus specific
anti-human-K-L-chain serum manifested creatine
kinase activity. Fluorescence could not be observed
by using anti-human-X-L-chain serum. \
Complexing in vitro
Increasing amounts of purified IgG from serum no. 11
were added to a constant concentration of creatine
kinase-BB, thus simulating an iramunotitration assay.
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Electrophoresis of the samples revealed the "atypical"
band of the IgG-creatine kinase-BB complex formed
in vitro (fig. 8). The titration point was estimated from
the IgG concentration required to complex all the
creatine kinase-BB present; this value was 18.6 U/g
IgG, representing a molecular ratio IgG: creatine kinase-
BB = 9000:1, assuming 320 U/mg for the specific
activity of pure creatine kinase-BB.
The interaction between creatine kinase-BB and the
purified IgG was further studied using the Ouchterlony
technique. As shown in figure 9 the precipitin line
between creatine kinase-BB and anti-creatine kinase-
BB serum was not disturbed by the presence of the
patient's IgG.
This result, and the observation that the purified IgG
slightly inhibited human creatine kinase-BB as well
as creatine kinase-MM, both to the same extent,
provided strong evidence for a rather nonspecific
protein-protein complex.Fig. 6.£tfnre//-electropherogram stained for creatine kinase
activity. Antigen: 15 μΐ of serum no. 5.
Antiserum: anti-human IgA serum; concentration on the
plate 5 ml/1.
Fig. 7. Immunoelectrophoresis pattern of serum no. 6 (top) and serum no. 8 (bottom) versus monospecific anti-IgG antiserum.
P: patient serum, N: control serum,
a) slide stained for creatine kinase activity b) slide stained with Coomassie BB.
Isoenzyme
BB
MB
MM _
Start"
cm
®
In vitro interaction of purified patient's IgG with human creatine kinase-BB. Increasing amounts of purified IgG (10.7 mg/ml)
were added to 35 mU creatine kinase-BB in Tris standard buffer pH 8.0
• .
 Λ , j . j A\ «,,;+Vi in
a) «ratine Unas* BB without any IgG added d) with 100 ;1 IgG
0 with 300 ,, IgG
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Fig. 9. Double immunodiffusion plate stained for creatine kinase activity.
1: human creatine kinase-BB, 2: purified IgG against creatine kinase-BB, 3: purified IgG of serum no. 11.
Discussion
The present results demonstrate that the atypical
creatine kinase isoenzyme pattern observed in
patients with high creatine kinase-BB levels was due
to complexing of creatine kinase-BB with the patients'
immunoglobulins. Urdal & Laudaas have come to
similar conclusions by using other techniques (20).
In 11 out of 12 cases studied, immunoglobulin G was
the complexing factor. In one case creatine kinase-BB
was linked to IgA.
The creatine kinase-BB activity in the complex was
extremely stable at 25 °C, 4 °C and 37 °C as compared
with the activity of native creatine kinase-BB stored
under similar conditions. These results could partly
explain the high concentration of creatine kinase-BB
and its prolonged appearance in the sera. The immuno-
titration curve and the formation of the complex
between purified IgG and exogenous creatine kinase-
BB in vitro both indicated that a normal creatine kinase-
BB protein was involved in the complex. On the other
hand the patients' immunoglobulins revealed normal
precipitin arcs as compared with control serum (fig. 7).
The stoichiometric composition of the complex was
estimated to be 1 : 1 from the molecular mass obtained
by gel filtration. The complexing capacity (mol IgG:
mol creatine kinase-BB) of the purified IgG was found
to be 9000:1 in the in vitro assay for case no. 11. Thus,
one out of 9000 molecules of that patient's IgG is able
to bind one molecule creatine kinase-BB. This ratio may,
however, vary from case to case. The complexing ability
of the immunoglobulins was further restricted to the /c-
L-class.
The assumption of antibody formation against creatine
kinase-BB could be excluded on the basis of the results
obtained by the immunotitration and the Ouchterlony
technique.
Complexing of immunoglobulins with enzymes is a well
known phenomenon in the clinical literature. Several
reports have described complex formation between
IgG and human enzymes, such as aspartate aminotrans-
ferase, lactate dehydrogenase and.alkaline phosphatase
(12,13,14). Binding may even occur between immuno-
globulins and plasma proteins (15).
Prabhakaran et al. recently reported the interaction of
human IgG with human creatine kinase-BB (16). The
described complex, however, is clearly distinct from
that reported in this paper, having a higher molecular
mass (825 000). Moreover, the lability of the high mole-
cular mass complex, discussed by the authors as a
possible route for creatine kinase-BB intravascular cata-
bolism, contrasts strongly with the stability of the 1:1
complex, discussed as a possible reaspre for the prolonged
occurrence of creatine kinase-BB in the patients' sera.
Atypical creatine kinase isoenzyme patterns have often
been reported. Velletri et al. described creatine kinase -
MM linked to /Mipoprotein and migrating between
creatine kinase-MM and creatine kinase-MB (17). A
similar mobility characterized the atypical pattern
reported by Sax et al. (18).
Previously we reported high creatine kinase-BB levels
present during 10 months in the serum of a patient
suffering from a nervous system disorder. The data
were obtained by immunotitration (5). On the basis
of the present results, complexing of creatine kinase-BB
with immunoglobulins might also have caused the
stability of creatine kinase-BB in that case. The fre-
quency of the "idiopathic" creatine kinase-BB presence
in patients' sera has been estimated to be 1:1000 (1)
or 1:100 (2).
In a recent study we demonstrated that the detection
and adequate estimation of the creatine kinase iso-
enzymes in these atypical sera-can only be achieved
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by using immunologieal methods able to distinguish
between creatine kinase-MB and creatine kinase-BB
(19). Even the immuno inhibition assay (Merck) can
lead to misinterpretation, especially when small amounts
of creatine kinase-BB are present and multiplication by
2 results in a "normal" creatine kinase-MB activity.
The main question, as to the tissue of origin of the high
creatine kinase-BB serum levels, remains, however, un-
solved. Since the nervous system and gastrointestinal
tract are the tissues with the highest creatine kinase-BB
concentration, they are both likely to be the source of
creatine kinase-BB. On the other hand, only one common
denominator could be found, namely the ability of the
patients' immunoglobulins to complex creatine kinase-
BB.
The thermal stability of the complexed enzyme in vitro
reasonably suggests that creatine kinase-BB is protected
in a similar way against intravascular degradation in vivo.
Serum creatine kinase-BB levels depend thus on the
serum concentration of the specific complexing immuno-
globulin L-chains and may reflect a normal cell efflux,
rather than any particular tissue or membrane damage.
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